Leap Therapeutics Q1 2025 Financial Update

Ticker: CYPH · Form: 10-Q · Filed: May 13, 2025 · CIK: 1509745

Leap Therapeutics, INC. 10-Q Filing Summary
FieldDetail
CompanyLeap Therapeutics, INC. (CYPH)
Form Type10-Q
Filed DateMay 13, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: financials, 10-Q, biotech

TL;DR

Leap Therapeutics Q1 2025: $41.4M assets, $3.8M liabilities. Solid financials.

AI Summary

Leap Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $41.4 million and total liabilities of $3.8 million as of March 31, 2025. This filing provides an update on the company's financial position and operational performance for the first quarter of 2025.

Why It Matters

This filing provides investors with a snapshot of Leap Therapeutics' financial health, including its assets and liabilities, which are crucial for assessing its operational capacity and investment potential.

Risk Assessment

Risk Level: medium — Biotech companies like Leap Therapeutics often face inherent risks related to drug development, clinical trials, and regulatory approvals, which can significantly impact financial performance.

Key Numbers

Key Players & Entities

FAQ

What were Leap Therapeutics' total assets as of March 31, 2025?

Leap Therapeutics reported total assets of $41,439,529 as of March 31, 2025.

What were Leap Therapeutics' total liabilities as of March 31, 2025?

Leap Therapeutics reported total liabilities of $3,832,989 as of March 31, 2025.

What is the reporting period for this 10-Q filing?

The conforming period of report for this 10-Q filing is March 31, 2025.

When was this 10-Q filing submitted?

This 10-Q filing was submitted on May 13, 2025.

What is Leap Therapeutics' Standard Industrial Classification code?

Leap Therapeutics' Standard Industrial Classification code is 2834, Pharmaceutical Preparations.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding LEAP THERAPEUTICS, INC. (CYPH).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing